Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial - PubMed
5 hours ago
- #mantle cell lymphoma
- #zanubrutinib
- #chemoimmunotherapy
- Zanubrutinib-rituximab followed by shortened chemoimmunotherapy (R-DHAOx) was evaluated as frontline treatment for mantle cell lymphoma (MCL) in a phase II trial (CHESS).
- Induction with zanubrutinib-rituximab for up to 12 cycles (part A) resulted in a complete response (CR) rate of 88%.
- Patients achieving CR or experiencing progression proceeded to four cycles of R-DHAOx (part B), with a CR rate of 86% after completion.
- Hematologic toxicities were common: grade 3-4 neutropenia (7%) in part A, and thrombocytopenia (77%) and neutropenia (49%) in part B.
- The regimen shows promising efficacy and manageable safety, allowing reduced chemotherapy cycles, warranting further validation in randomized trials.